TRIANEX® 0.05%(Triamcinolone Acetonide Ointment,USP) Now Available from Promius Pharma®, LLC

  • 1
  • March 05, 2015

trianexFarmville, NC – March 5, 2015 – CMP Pharma, Inc. has licensed the marketing and distribution rights for Trianex® to Promius Pharma, LLC. Trianex ® a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of a cream. It is also the only Triamcinolone Acetonide topical available in 0.05% strength.

“We are pleased to collaborate with Promius Pharma on Trianex® through this licensing arrangement and look forward to a successful and longstanding relationship” said Gerry Sakowski, CEO of CMP Pharma, Inc.

Trianex® Ointment is available in a 430 gram jar and features a proprietary cream-like formulation. It will be the only triamcinolone acetonide 0.05% ointment to offer this configuration, making it an appealing option for those patients with steroid responsive skin conditions that cover large areas and who don’t like the typical greasy feel of ointments.

CMP Pharma, Inc. will continue to manufacture the product for Promius Pharma.

Promius Pharma is a registered trademark of Promius Pharma LLC

Trianex® Indication and Important Safety Information

Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with Trianex Ointment include burning, itching, irritation, dryness, and folliculitis. Trianex Ointment is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

Please visit www.trianexointment.com for Full Prescribing Information.

About CMP Pharma, Inc.

CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and liquid oral dose pharmaceutical products. The company was founded in the early 1980s around the development of a ready-to-use liquid dosage form for sodium polystyrene sulfonate, a drug used for the treatment of hyperkalemia. For more information visit www.cmppharma.com.

Trianex is a registered trademark of CMP Pharma, Inc.

CONTACT: Gerald Sakowski, CEO, CMP Pharma, Inc. 252 753-7111